secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001437749-24-037053
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed Phase 2b DLB trial fails primary and secondary endpoints; neflamapimod no better than placebo
--------------------------------------------------------------------------------

- Neflamapimod did not demonstrate statistically significant effects vs placebo on CDR-SB, TUG, NTD, or CGIC at 16 weeks.
- Target plasma drug concentrations were not achieved during double-blind phase, likely negatively impacting results.
- Favorable safety/tolerability profile with no new safety signal identified.
- Company pausing all Phase 3 preparations for early-stage DLB until full analysis complete.
- Full double-blind data expected January 2025; open-label first 16 weeks data expected late Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924037053/0001437749-24-037053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924037053/crvo20241209_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-037053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer